You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

VALDECOXIB - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for valdecoxib and what is the scope of patent protection?

Valdecoxib is the generic ingredient in one branded drug marketed by Gd Searle and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for VALDECOXIB
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 128
Clinical Trials: 30
Patent Applications: 7,355
DailyMed Link:VALDECOXIB at DailyMed
Recent Clinical Trials for VALDECOXIB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Sao PauloPhase 4
University of PennsylvaniaPhase 1
National Heart, Lung, and Blood Institute (NHLBI)Phase 1

See all VALDECOXIB clinical trials

US Patents and Regulatory Information for VALDECOXIB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-003 Nov 16, 2001 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-002 Nov 16, 2001 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VALDECOXIB

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-002 Nov 16, 2001 ⤷  Sign Up ⤷  Sign Up
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-003 Nov 16, 2001 ⤷  Sign Up ⤷  Sign Up
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-003 Nov 16, 2001 ⤷  Sign Up ⤷  Sign Up
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-002 Nov 16, 2001 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for VALDECOXIB

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pharmacia - Pfizer EEIG Bextra valdecoxib EMEA/H/C/000431
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).
Withdrawn no no no 2003-03-27
Pfizer Limited Valdyn (previously Kudeq) valdecoxib EMEA/H/C/000437
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.
Withdrawn no no no 2003-03-27
Pharmacia Europe EEIG Valdyn valdecoxib EMEA/H/C/000432
Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.Treatment of primary dysmenorrhoea.
Withdrawn no no no 2003-03-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.